Onfi FDA Approved Drugs
ALDARA [ImiquimodC14H16N4]
RX
- 5% (topical cream)
MedicisFeb 27, 1997
- Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc).
- Works through the induction of interferon and other cytokines.
AUGMENTIN XR [AmoxicillinC16H19N3O5S3H2O : Clavulanate PotassiumC8H8NO5K]
RX
- 1gm : eq 62.5mg base (oral tablet, extended release)
Dr Reddys Labs IncSep 25, 2002
- Mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & s. pneumoniae with reduced susceptibility to penicillin (mic=2mc/ml).
EXONDYS 51 [Eteplirsen]
RX
- 100mg/2ml (50mg/ml) (iv (infusion) solution)
500mg/10ml (50mg/ml) (iv (infusion) solution)
Sarepta Theraps IncSep 19, 2016
- (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; or (iii) inducing skipping; each of (i)-(iii) in patients having a confirmed mutation of the dmd gene that is amenable to exon 51 skipping.
- Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping.
- Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping.
ONFI [ClobazamC16H13ClN2O2]
RX
- 10mg (oral tablet)
2.5mg/ml (oral suspension)
20mg (oral tablet)
Lundbeck Pharms LlcOct 21, 2011
TAFINLAR [Dabrafenib MesylateC23H20F3N5O2S2CH4O3S]
RX
- eq 50mg base (oral capsule)
eq 75mg base (oral capsule)
Novartis Pharms CorpMay 29, 2013
- Tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma.
- Treatment of melanoma.
- Treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.